GLP-1受体激动剂和急性胰腺炎：事实或夸大的风险？

IF 4 4区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Revista Espanola De Enfermedades Digestivas Pub Date : 2025-09-29 DOI:10.17235/reed.2025.11499/2025

Juan Enrique Domínguez Muñoz, José Lariño Noia, Yessica Domínguez Novoa, Julio Iglesias-García

{"title":"GLP-1受体激动剂和急性胰腺炎：事实或夸大的风险？","authors":"Juan Enrique Domínguez Muñoz, José Lariño Noia, Yessica Domínguez Novoa, Julio Iglesias-García","doi":"10.17235/reed.2025.11499/2025","DOIUrl":null,"url":null,"abstract":"Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely prescribed for type 2 diabetes mellitus (T2DM) and weight management. These medications mimic the effects of the intestinal hormone GLP-1, thereby enhancing insulin secretion, reducing glucagon release, inducing satiety, and slowing gastric emptying. Their therapeutic scope now extends to cardiometabolic conditions and metabolic-associated steatotic liver disease (MASLD). Despite their clinical utility, GLP-1 RAs are frequently associated with gastrointestinal adverse effects-including nausea, vomiting, and diarrhoea-reported in up to 80% of patients, often in a dose-dependent manner. Concerns have also emerged regarding a potential association with acute pancreatitis.","PeriodicalId":21342,"journal":{"name":"Revista Espanola De Enfermedades Digestivas","volume":" ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"GLP-1 receptor agonists and acute pancreatitis: fact or overstated risk?\",\"authors\":\"Juan Enrique Domínguez Muñoz, José Lariño Noia, Yessica Domínguez Novoa, Julio Iglesias-García\",\"doi\":\"10.17235/reed.2025.11499/2025\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely prescribed for type 2 diabetes mellitus (T2DM) and weight management. These medications mimic the effects of the intestinal hormone GLP-1, thereby enhancing insulin secretion, reducing glucagon release, inducing satiety, and slowing gastric emptying. Their therapeutic scope now extends to cardiometabolic conditions and metabolic-associated steatotic liver disease (MASLD). Despite their clinical utility, GLP-1 RAs are frequently associated with gastrointestinal adverse effects-including nausea, vomiting, and diarrhoea-reported in up to 80% of patients, often in a dose-dependent manner. Concerns have also emerged regarding a potential association with acute pancreatitis.\",\"PeriodicalId\":21342,\"journal\":{\"name\":\"Revista Espanola De Enfermedades Digestivas\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2025-09-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Espanola De Enfermedades Digestivas\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.17235/reed.2025.11499/2025\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola De Enfermedades Digestivas","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.17235/reed.2025.11499/2025","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

胰高血糖素样肽-1受体激动剂（GLP-1 RAs）广泛用于2型糖尿病（T2DM）和体重管理。这些药物模拟肠道激素GLP-1的作用，从而增加胰岛素分泌，减少胰高血糖素释放，诱导饱腹感，减缓胃排空。它们的治疗范围现已扩展到心脏代谢疾病和代谢相关脂肪变性肝病（MASLD）。尽管具有临床用途，GLP-1 RAs经常与胃肠道不良反应相关，包括恶心、呕吐和腹泻，据报道，高达80%的患者出现了这种不良反应，通常呈剂量依赖性。也出现了与急性胰腺炎的潜在关联的担忧。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

GLP-1 receptor agonists and acute pancreatitis: fact or overstated risk?

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely prescribed for type 2 diabetes mellitus (T2DM) and weight management. These medications mimic the effects of the intestinal hormone GLP-1, thereby enhancing insulin secretion, reducing glucagon release, inducing satiety, and slowing gastric emptying. Their therapeutic scope now extends to cardiometabolic conditions and metabolic-associated steatotic liver disease (MASLD). Despite their clinical utility, GLP-1 RAs are frequently associated with gastrointestinal adverse effects-including nausea, vomiting, and diarrhoea-reported in up to 80% of patients, often in a dose-dependent manner. Concerns have also emerged regarding a potential association with acute pancreatitis.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Revista Espanola De Enfermedades Digestivas 医学-胃肠肝病学

CiteScore

2.00

自引率

25.00%

发文量

400

审稿时长

6-12 weeks

期刊介绍： La Revista Española de Enfermedades Digestivas, Órgano Oficial de la Sociedad Española de Patología Digestiva (SEPD), Sociedad Española de Endoscopia Digestiva (SEED) y Asociación Española de Ecografía Digestiva (AEED), publica artículos originales, editoriales, revisiones, casos clínicos, cartas al director, imágenes en patología digestiva, y otros artículos especiales sobre todos los aspectos relativos a las enfermedades digestivas.